A Phase 2 Study to Evaluate the Safety and Efficacy of Atacicept in Multiple Autoimmune Glomerular Diseases (PIONEER)
To learn about the effects of the medication, Atacicept, on decreasing kidney damage for people with autoimmune glomerular disease
Why this Research Matters
Participants will do self-injections, just under the skin, of the study drug once a week for approximately 9 months and will then be monitored for an additional 6 months.
Who can Participate
Adults with one of the following kidney diseases: IgA nephropathy (IgAN or Berger's Disease), IgA vasculitis with nephritis (IgAVN or Henoch Schonlein Purpura), primary membranous nephropathy (pMN) or minimal change disease and focal segmental glomerular sclerosis (MCD and FSGS) -at least 18 years old -weight at least 40kg -stable blood pressure -diagnosis of IgA vasculitis or FSGS or MCD or IgAN or pMN -not on dialysis -no uncontrolled diabetes -no tuberculosis -no history of multiple sclerosis or optic neuritis -no history of significant heart issues -no history of acute or chronic HIV, Hep B or HepC -no history of splenectomy -no cancer within the last 5 years (with the exception of some skin cancers and cervical cancer) -no significant drug or alcohol abuse within 1 year .
Study ID
Protocol Number: 25-1324
Meet the Team
James Dylewski
Principal Investigator